Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, Bristol-Myers Squibb (NYSE:BMY) has gotten the green light from the U.K.'s National Institute of Clinical Excellence for its arthritis drug Orencia. The drug is one of BMY's best performers from last quarter, but there is a lot of big-name competition in this space, and Bristol still has other lingering issues hanging over its head.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.